# US 2017/0281580 A1 · Topical diclofenac sodium compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281580 A1
- Document ID: US20170281580A1
- Status: Published application
- Kind: A1
- Application number: 15/506,774
- Filed: 2015-09-09
- Published: 2017-10-05
- Earliest claimed: 2014-09-10
- Assignees: Novartis Consumer Health S.A.
- Applicants: Novartis Consumer Health S.A.
- Inventors: Gregory JOHNSON; Eric WOODWARD
- Web page: https://patentgrep.com/patent/US20170281580A1

## CPC

- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 47/00: Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to beneficial topical pharmaceutical compositions comprising diclofenac sodium in high amounts, and methods for their use. Said compositions represent emulsion-gels as well as gels with unique properties such as high skin penetration, no irritation, high stability, complete dissolution of the active and effective pain relief. The invention also provides methods for treating pain or inflammation in a mammalian subject in need thereof, including acute and chronic pain or inflammation; and kits therefor.

## Claims

### Claim 1

A topical pharmaceutical composition which comprises:
(a) 1-5% of diclofenac sodium,
(b) at least about 50% of water,
(c) from about 5 to about 20% of at least one C2-C4-alkanol,
(d) from about 5 to about 25% of a glycol solvent selected from the group consisting of propylene glycol and polyethylene glycol (200-20000),
(e) from about 0.2 to about 5% of at least one gelling agent selected from the group consisting of carbomers, mixtures of carbomers, and mixtures of one or more carbomers with one or more hydroxy- and/or carboxy-substituted celluloses,
(f) from 0 to about 10% of a liquid lipid forming an oil phase,
(g) from 0 to about 5% of at least one non-ionic surfactant, and
(h) a basic agent to adjust the pH of the total composition to 6-9,
all percentages being by weight (w/w).

### Claim 2 (depends on 1)

A topical pharmaceutical composition according to claim 1 wherein (a) comprises 2% diclofenac sodium salt.

### Claim 3 (depends on 1)

A topical pharmaceutical composition according to claim 1 wherein (c) comprises isopropyl alcohol.

### Claim 4 (depends on 1)

A topical pharmaceutical composition according to claim 1 wherein (d) comprises propylene glycol.

### Claim 5 (depends on 1)

A topical pharmaceutical composition according to claim 1, in the form of an emulsion gel, comprising:
(f) from about 2 to about 8% (w/w) of at least one lipid forming the oil phase of the emulsion gel; and
(g) from about 1 to about 5% (w/w) of at least one non-ionic surfactant.

### Claim 6 (depends on 5)

A topical pharmaceutical composition according to claim 5 wherein (f) comprises mineral oil and cocoyl caprylocaprate and (g) is selected from the group consisting of esters of fatty acids with monohydroxy or polyhydroxy compounds, polyoxyethylated surfactants and mixtures thereof.

### Claim 7 (depends on 1)

A topical pharmaceutical composition according to claim 1, in the form of a gel, which is essentially free of (f).

### Claim 8 (depends on 7)

A topical pharmaceutical composition according to claim 7, which is essentially free of (f) and (g).

### Claim 9

A topical pharmaceutical composition which comprises:
(a) 2% of diclofenac sodium salt,
(b) at least about 55% of water,
(c) from about 10 to about 20% of at least one C2-C4-alkanol,
(d) from about 10 to about 20% of at least one glycol solvent selected from the group consisting of 1,2-propanediol and polyethylene glycol (200-20000),
(e) from about 0.5 to about 5% of at least one gelling agent selected from the group consisting of carbomers,
(f) from 0 to about 10% of a lipid forming an oil phase,
(g) from 0 to about 5% of at least one non-ionic surfactant, and
(h) a basic agent to adjust the pH of the total composition to 6-9.

### Claim 10 (depends on 9)

A topical pharmaceutical composition according to claim 9, wherein (c) comprises isopropyl alcohol.

### Claim 11 (depends on 9)

A topical pharmaceutical composition according to claim 9, wherein (d) comprises propylene glycol.

### Claim 12 (depends on 9)

A topical pharmaceutical composition according to claim 9 in the form of an emulsion gel, comprising:
(f) from about 2 to about 8% (w/w) of at least one lipid forming the oil phase of the emulsion gel; and
(g) from about 1 to about 5% (w/w) of at least one non-ionic surfactant.

### Claim 13 (depends on 12)

A topical pharmaceutical composition according to claim 12 wherein (f) comprises mineral oil and cocoyl caprylocaprate and (g) is selected from the group consisting of esters of fatty acids with monohydroxy or polyhydroxy compounds, poly(oxyethylated surfactants and mixtures thereof.

### Claim 14 (depends on 9)

A topical pharmaceutical composition according to claim 9, in the form of a gel, which is essentially free of (f).

### Claim 15 (depends on 14)

A topical pharmaceutical composition according to claim 14, which is essentially free of (f) and (g).

### Claim 16

A topical pharmaceutical composition, in the form of an emulsion gel, which comprises:
(a) 2% (w/w) of diclofenac sodium salt,
(b) at least about 60% of water,
(c) from about 10 to about 15% of at least one C2-C4-alkanol,
(d) from about 10 to about 15% of at least one glycol solvent selected from the group consisting of 1,2-propanediol and polyethylene glycol (200-20000),
(e) from about 0.7 to about 3% of at least one gelling agent selected from the group consisting of carbomers, and
(f) from about 3 to about 7% of at least one liquid lipid forming the oily phase of the emulsion-gel,
(g) from about 1 to about 3% of at least one non-ionic surfactant, and
(h) from about 0.5 to about 3% of a base to adjust the pH of the total composition to 7-9,

### Claim 17 (depends on 16)

A topical pharmaceutical composition according to claim 16 wherein (c) comprises isopropyl alcohol.

### Claim 18 (depends on 16)

A topical pharmaceutical composition according to claim 16 wherein (d) comprises propylene glycol.

### Claim 19 (depends on 16)

A topical pharmaceutical composition according to claim 16 wherein (e) is selected from carbomers and mixtures thereof.

### Claim 20 (depends on 16)

A topical pharmaceutical composition according to claim 16 wherein (f) comprises mineral oil and cocoyl caprylocaprate and (g) is selected from the group consisting of esters of fatty acids with monohydroxy or polyhydroxy compounds, polyoxyethylated surfactants and mixtures thereof.

### Claim 21 (depends on 16)

A topical pharmaceutical composition according to claim 16 wherein (g) comprises polyoxyl 20 cetostearyl ether.

### Claim 22

A topical pharmaceutical composition, in the form of an emulsion gel, which comprises:
(a) 2% (w/w) of diclofenac sodium salt,
(b) at least about 60% of water,
(c) from about 10 to about 15% of isopropanol,
(d) from about 10 to about 15% of propylene glycol,
(e) from about 0.7 to about 3% of carbomer or mixtures thereof,
(f) from about 3 to about 7% of at least one liquid lipid forming the oily phase of the emulsion-gel selected from mineral oil and cocoyl caprylocaprate, and mixtures thereof,
(g) from about 1 to about 3% of polyoxyl 20 ceetostearyl ether, and
(h) a basic agent to adjust the pH of the total composition to 7-9.

### Claim 23 (depends on 1)

A topical pharmaceutical composition according to claim 1, which is in the form of an emulsion-gel or gel and comprises 1-5% (w/w) of diclofenac sodium salt; (A) said composition having a high skin permeation, (B) said composition showing a very low systemic absorption only, (C) said composition showing essentially no irritation on human skin after administration, and (D) said composition being chemically and physically stable when stored at 25° C. and a relative humidity of 60% for 12 months, in that (i) that the emulsion-gel structure of the composition is maintained without breaking of the emulsion, and (ii) that the original color of the composition does not visibly change, e.g. via yellowing, over a period of at least 12 months when stored at 25° C. and at a relative humidity of 60%, and (E) said composition further keeping the diclofenac sodium salt fully dissolved, which means that even upon microscopic examination essentially no crystals of diclofenac sodium salt can be observed therein.

### Claim 24 (depends on 1)

A method for treating pain or inflammation in a mammalian subject comprising topically administering a therapeutically effective amount of a composition according to claim 1 to a mammalian subject in need thereof.

### Claim 25 (depends on 24)

A method according to claim 24 for treating acute pain or inflammation.

### Claim 26 (depends on 24)

A method according to claim 24 for treating chronic pain or inflammation.

### Claim 27 (depends on 1)

A method for treating a mammalian subject in need thereof to provide temporary relief from mild-to-moderate aches and pains of muscles and joints associated with conditions selected from one or more of arthritis, strains, sprains, bruises and backache, by administering to the subject a therapeutically effective amount of a composition according to claim 1.

### Claim at position 28

28-30. (canceled)

### Claim 31 (depends on 1)

A composition according to claim 1 for administration to a mammalian subject in need thereof to provide temporary relief from mild-to-moderate aches and pains of muscles and joints associated with conditions selected from one or more of arthritis, strains, sprains, bruises and backache.

### Claim 32 (depends on 1)

A kit for administering a composition for the treatment of pain or inflammation comprising
(a) a composition according to claim 1
(b) instructions for topically administering the composition, and optionally
(c) a pre-calibrated dosing device.
